6660 logo

AIM VaccineSEHK:6660 Stock Report

Market Cap HK$6.1b
Share Price
HK$5.08
My Fair Value
AN
AnalystConsensusTarget
HK$11
54.6% undervalued intrinsic discount
1Y-20.7%
7D26.4%
Portfolio Value
View

AIM Vaccine Co., Ltd.

SEHK:6660 Stock Report

Market Cap: HK$6.1b

AIM Vaccine (6660) Stock Overview

Engages in the research and development, manufacture, and sale of vaccine products for human use in the People’s Republic of China. More details

6660 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

6660 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

AIM Vaccine Co., Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for AIM Vaccine
Historical stock prices
Current Share PriceHK$5.08
52 Week HighHK$15.48
52 Week LowHK$3.03
Beta0.16
1 Month Change34.39%
3 Month Change54.41%
1 Year Change-20.75%
3 Year Changen/a
5 Year Changen/a
Change since IPO-69.51%

Recent News & Updates

AIM Vaccine Co., Ltd.'s (HKG:6660) Share Price Boosted 32% But Its Business Prospects Need A Lift Too

Jul 24
AIM Vaccine Co., Ltd.'s (HKG:6660) Share Price Boosted 32% But Its Business Prospects Need A Lift Too

Recent updates

AIM Vaccine Co., Ltd.'s (HKG:6660) Share Price Boosted 32% But Its Business Prospects Need A Lift Too

Jul 24
AIM Vaccine Co., Ltd.'s (HKG:6660) Share Price Boosted 32% But Its Business Prospects Need A Lift Too

Take Care Before Jumping Onto AIM Vaccine Co., Ltd. (HKG:6660) Even Though It's 25% Cheaper

Apr 04
Take Care Before Jumping Onto AIM Vaccine Co., Ltd. (HKG:6660) Even Though It's 25% Cheaper

Here's Why AIM Vaccine (HKG:6660) Can Afford Some Debt

Nov 15
Here's Why AIM Vaccine (HKG:6660) Can Afford Some Debt

Why Investors Shouldn't Be Surprised By AIM Vaccine Co., Ltd.'s (HKG:6660) 27% Share Price Plunge

Aug 24
Why Investors Shouldn't Be Surprised By AIM Vaccine Co., Ltd.'s (HKG:6660) 27% Share Price Plunge

It's A Story Of Risk Vs Reward With AIM Vaccine Co., Ltd. (HKG:6660)

May 29
It's A Story Of Risk Vs Reward With AIM Vaccine Co., Ltd. (HKG:6660)

Investor Optimism Abounds AIM Vaccine Co., Ltd. (HKG:6660) But Growth Is Lacking

Jun 09
Investor Optimism Abounds AIM Vaccine Co., Ltd. (HKG:6660) But Growth Is Lacking

Shareholder Returns

6660HK BiotechsHK Market
7D26.4%3.2%4.3%
1Y-20.7%174.0%44.2%

Return vs Industry: 6660 underperformed the Hong Kong Biotechs industry which returned 174% over the past year.

Return vs Market: 6660 underperformed the Hong Kong Market which returned 44.2% over the past year.

Price Volatility

Is 6660's price volatile compared to industry and market?
6660 volatility
6660 Average Weekly Movement8.5%
Biotechs Industry Average Movement10.3%
Market Average Movement6.9%
10% most volatile stocks in HK Market15.3%
10% least volatile stocks in HK Market3.4%

Stable Share Price: 6660 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Volatility Over Time: 6660's weekly volatility has decreased from 17% to 9% over the past year.

About the Company

FoundedEmployeesCEOWebsite
20111,535Yan Zhouwww.aimbio.com

AIM Vaccine Co., Ltd. engages in the research and development, manufacture, and sale of vaccine products for human use in the People’s Republic of China. The company’s product pipeline includes tetravalent meningococcal conjugate vaccine, which is in phase IV clinical trial for meningococcal disease 13-Valent pneumonia conjugate and 23-valent pneumonia polysaccharide vaccine to treat pneumonia; iterative serum-free rabies vaccine; and bivalent Delta-Omicron BA.5 mRNA COVID-19 vaccine that is in phase III clinical trial to treat COVID-19 infection. It also offers tetravalent meningococcal polysaccharide and conjugate vaccine, which is in phase II trials for the treatment of meningococcal disease; and EV71-CA16 Bivalent HFMD vaccine.

AIM Vaccine Co., Ltd. Fundamentals Summary

How do AIM Vaccine's earnings and revenue compare to its market cap?
6660 fundamental statistics
Market capHK$6.08b
Earnings (TTM)-HK$303.75m
Revenue (TTM)HK$1.41b
4.4x
P/S Ratio
-20.5x
P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6660 income statement (TTM)
RevenueCN¥1.29b
Cost of RevenueCN¥331.52m
Gross ProfitCN¥953.51m
Other ExpensesCN¥1.23b
Earnings-CN¥277.23m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.23
Gross Margin74.20%
Net Profit Margin-21.57%
Debt/Equity Ratio50.4%

How did 6660 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/25 10:12
End of Day Share Price 2025/07/25 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

AIM Vaccine Co., Ltd. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullFosun International Securities Limited
Tony RenMacquarie Research